Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. (Q43636904)

25 November 2017

Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. (English)

1 reference

25 November 2017

1 reference

human papillomavirus 16

1 reference

5

Hiroyuki Yoshikawa

1 reference

25 November 2017

4

Koji Matsumoto

1 reference

25 November 2017

1

Sari Nakao

1 reference

25 November 2017

3

Kazunari Kondo

1 reference

25 November 2017

6

Tadahito Kanda

1 reference

25 November 2017

2

Seiichiro Mori

1 reference

PubMed ID

23051711

25 November 2017

language of work or name

English

0 references

publication date

7 October 2012

1 reference

25 November 2017

1 reference

25 November 2017

434

1 reference

25 November 2017

1

1 reference

25 November 2017

110-117

1 reference

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Efficient intracellular assembly of papillomaviral vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Arrangement of L2 within the papillomavirus capsid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Overlapping and independent structural roles for human papillomavirus type 16 L2 conserved cysteines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Immunological analyses of human papillomavirus capsids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

A multimeric L2 vaccine for prevention of animal papillomavirus infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Infectious human papillomavirus type 18 pseudovirions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3' to 5' exonuclease activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2012.09.006

10.1016/J.VIROL.2012.09.006

7 January 2021

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

23051711